Ketamine’s plasma half-life generally falls in the range of about two to three hours after a single dose, though published figures span from roughly 1.5 to 5 hours depending on the route of administration, liver function, and individual metabolism.1PubMed. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans That range is wider than you might expect for a single drug, and the reasons behind it matter whether you are a patient receiving ketamine for depression or pain, a clinician adjusting an infusion, or someone trying to understand how long the drug’s effects linger after the last dose.
What “Half-Life” Actually Tells You Here
A classic pharmacokinetic study in healthy volunteers measured ketamine’s terminal elimination half-life at about 186 minutes, or just over three hours, after intravenous dosing.2PubMed. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans A clinical toxicology review puts the overall human range at 1.5 to 5 hours.3Clinical Toxicology. The clinical toxicology of ketamine In practical terms, after a single IV dose, most of the drug has cleared from your bloodstream within about 10 to 12 hours (roughly four to five half-lives). But “cleared from the bloodstream” and “no longer affecting the body” are not the same thing. Ketamine gets converted into active metabolites that carry their own timelines, and the drug itself can become physically trapped inside certain brain receptors, extending its influence well past what a blood draw would predict.
How Route of Administration Changes the Numbers
The way ketamine enters the body has a dramatic effect on how much reaches the bloodstream and how quickly it peaks and fades. When given intravenously, the drug hits the circulation immediately and produces the textbook half-life of roughly two to three hours. Intramuscular injection is almost as efficient, with about 93% of the dose reaching the blood, and absorption is rapid.4PubMed. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans
Oral ketamine is a different story. Only about 17% of an oral dose makes it into the bloodstream because the liver metabolizes most of the drug before it ever reaches general circulation.5PubMed. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans That heavy first-pass metabolism is the reason oral doses need to be substantially larger to achieve clinical effects. It also means the oral route generates proportionally far more of the metabolite norketamine, which has its own pharmacological activity and its own half-life. Some researchers argue that oral ketamine’s therapeutic effects on pain are driven more by norketamine than by ketamine itself.6PubMed Central. Oral ketamine may offer a solution to the ketamine conundrum
Nasal administration, used clinically with the esketamine spray Spravato, offers a middle ground. Nasal delivery produces relatively rapid peak concentrations with higher bioavailability than oral dosing, sidestepping some of that first-pass metabolism.7PubMed. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy Sublingual formulations work on a similar principle, letting the drug absorb through mucous membranes rather than traveling through the gut first.
How the Liver Processes Ketamine
Ketamine is broken down primarily in the liver through a process called N-demethylation, which strips off a methyl group and converts the drug into norketamine. The principal liver enzyme responsible for this conversion is CYP3A4, with smaller contributions from CYP2B6 and CYP2C9.8PubMed. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes This detail matters because CYP3A4 is one of the most commonly involved enzymes in drug interactions. Anything that inhibits or speeds up CYP3A4 can change how quickly ketamine clears.
These enzymes are also genetically variable from person to person. People carry different versions of the genes coding for CYP2B6, CYP3A4, CYP2C9, and CYP2A6, all of which play a role in ketamine metabolism.9PubMed. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant – implications for precision dosing in a global perspective Someone who is a slow metabolizer for one or more of these enzymes will clear ketamine more slowly, pushing their effective half-life toward the longer end of the 1.5-to-5-hour range. The reverse is also true: rapid metabolizers may process the drug faster than average.
After norketamine is formed, it undergoes further metabolism. The cyclohexane ring gets hydroxylated, then those hydroxylated products are conjugated with glucuronic acid and eventually excreted in urine. Very little ketamine leaves the body unchanged: only about 2% is excreted in urine as the parent drug. Another 2% appears as norketamine, about 16% as dehydronorketamine, and roughly 80% as glucuronide conjugates of hydroxylated metabolites.10PubMed Central. Metabolism and metabolomics of ketamine: a toxicological approach
Norketamine and the Metabolite Timeline
Norketamine, the first and most studied metabolite, is itself pharmacologically active. It has roughly one-third the anesthetic potency of ketamine, and researchers believe it contributes meaningfully to the drug’s analgesic effects. In pediatric modeling studies, norketamine’s elimination half-life was measured at about 1.1 hours, compared to roughly 2.1 hours for the parent drug.11PubMed. Modeling the norketamine metabolite in children and the implications for analgesia So norketamine itself clears faster than ketamine, but because it continues to be formed as long as ketamine is present, it extends the overall window of pharmacological activity. Simulations from that same study suggested norketamine could contribute to pain relief for about four hours after a single IV bolus dose.
Beyond norketamine, the drug breaks down further into hydroxynorketamines (HNKs), a family of at least 12 distinct compounds. These have attracted intense interest in depression research because some HNKs appear to produce antidepressant-like effects in animal models through mechanisms that do not require the same kind of receptor blockade ketamine uses. Different HNK variants reach very different peak levels in the brain and blood, meaning the metabolite picture is far from simple.12PubMed Central. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines The point for the reader is that ketamine’s effective duration involves a cascade of active breakdown products, not just the parent molecule ticking down to zero.
Context-Sensitive Half-Time During Continuous Infusions
If you are receiving ketamine as a continuous drip rather than a single shot, the relevant number is not the terminal elimination half-life but something called the context-sensitive half-time. This describes how long it takes for blood levels to drop by 50% after the infusion stops, and it gets longer the longer you have been on the drip. That happens because ketamine is lipid-soluble and gradually saturates body fat and other deep tissue compartments during a prolonged infusion. When the infusion ends, those tissues slowly release the stored drug back into the bloodstream.
In children, this value rises from about 30 minutes after a one-hour infusion to roughly 55 minutes after a five-hour infusion, which is notably shorter than the corresponding adult numbers.13PubMed. Ketamine anesthesia in children–exploring infusion regimens Children generally metabolize ketamine faster than adults, which is one reason pediatric dosing protocols differ from adult ones. For clinicians titrating a ketamine infusion, the context-sensitive half-time is more useful than the standard half-life figure because it predicts how quickly a patient will wake up or lose analgesia once the drip stops.
What Slows Down Clearance
Liver Impairment
Because the liver does almost all the heavy lifting in ketamine metabolism, liver disease can substantially extend how long the drug stays in the body. Data from the nasal esketamine product (Spravato) showed that patients with moderate liver impairment had roughly double the total drug exposure compared to patients with normal liver function, and the measured half-life of esketamine in the moderate impairment group averaged about 18.7 hours versus 16.5 hours in healthy controls.14Janssen Medical Information. SPRAVATO – Hepatic Adverse Events and Use in Patients with Hepatic Impairment Those half-life values for intranasal esketamine are considerably longer than the two-to-three-hour figure typically cited for IV racemic ketamine, partly because the nasal formulation has its own absorption and distribution profile. The broader lesson is that compromised liver function can meaningfully slow ketamine clearance, and dose adjustments are warranted.
Age
Age affects ketamine pharmacokinetics at both extremes. Children tend to clear the drug faster than adults, as reflected in their shorter context-sensitive half-times. At the other end, aging slows clearance. Animal research in aged versus young rats found that the elimination rate constant dropped substantially in older animals, extending the half-life and leaving measurable drug levels in plasma for days rather than hours after a single dose.15PubMed Central. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats While animal data does not translate directly to human dosing, it aligns with the general principle that older adults often metabolize drugs more slowly due to reduced liver blood flow and enzyme activity.
Drug Interactions That Extend Half-Life
Because CYP3A4 is the primary enzyme clearing ketamine, any drug that strongly inhibits CYP3A4 can meaningfully extend ketamine’s half-life and increase its blood levels. In a rat model, co-administration with voriconazole (a potent antifungal and strong CYP3A4 inhibitor) significantly increased both the peak concentration and total exposure of ketamine while prolonging its elimination half-life.16PubMed. The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine The same study showed that clearance dropped and the volume of distribution expanded, consistent with the two drugs competing for the same enzyme binding sites.
This interaction is not limited to prescription drugs. In a crossover trial with healthy volunteers, five days of drinking grapefruit juice (a well-known CYP3A4 inhibitor) tripled the total exposure to oral S-ketamine, doubled the peak concentration, and increased the elimination half-life by about 24%.17The Journal of Clinical Psychiatry. Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions The interaction was most pronounced with the oral route, where first-pass metabolism normally destroys most of the drug. When that first-pass activity is inhibited, much more ketamine gets through to the bloodstream. If you are taking oral ketamine for pain or depression, even common dietary CYP3A4 inhibitors like grapefruit can make a clinically meaningful difference.
Other strong CYP3A4 inhibitors that could theoretically slow ketamine clearance include certain HIV protease inhibitors, some macrolide antibiotics like clarithromycin, and several azole antifungals beyond voriconazole. In the opposite direction, CYP3A4 inducers such as rifampin, carbamazepine, and St. John’s wort could accelerate ketamine metabolism and shorten its effective duration, though this has been less thoroughly studied in clinical settings.
How Long Ketamine Shows Up on Tests
Blood and urine detection windows do not perfectly mirror the half-life, because the metabolites linger much longer than the parent drug. Since about 98% of ketamine is excreted as metabolites rather than unchanged drug, standard urine immunoassays typically look for norketamine or dehydronorketamine.18PubMed Central. Metabolism and metabolomics of ketamine: a toxicological approach Depending on the dose, frequency of use, and the sensitivity of the assay, urine tests can detect ketamine metabolites for several days after a single dose and potentially longer after repeated use.
Hair testing operates on an entirely different timescale. In a case study of a patient who had received repeated therapeutic ketamine, ketamine was still detectable in hair four months after the last treatment. The concentration dropped by about 97% over that period, and the estimated elimination half-life in hair was about 0.88 months, suggesting the drug would become undetectable roughly seven months after cessation of treatment.19PubMed. The duration of ketamine detection in hair after treatment cessation: Case study and review of the literature in forensic and clinical casework Hair testing is mainly relevant in forensic and workplace contexts, not clinical ones, but it is worth knowing if you have received ketamine therapeutically and face hair-based drug screening.
Why Effects Can Outlast Blood Levels
One of the more striking findings in recent ketamine research is that its antidepressant effects can persist for days or even a week or more after a single dose, long after the drug and its metabolites have been eliminated from the blood. Part of this likely reflects downstream changes in brain signaling and synaptic connections that ketamine triggers but that persist independently of the drug’s continued presence. But there may also be a more direct pharmacological explanation.
Ketamine blocks a type of brain receptor called the NMDA receptor by entering the channel pore when the channel opens. Researchers have found that once ketamine is inside the channel, the channel can close around it, physically trapping the molecule. The drug then sits inside the receptor, unable to wash out, until the channel happens to open again. In a 2023 study, brain slices from a region called the lateral habenula still showed strong NMDA receptor inhibition hours after the tissue had been bathed in ketamine-free solution, well past the point when any free ketamine should have washed away.20Nature. Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb This trapping mechanism may help explain why a drug with a two-to-three-hour plasma half-life can produce mood effects that last for days. The blood might be clear, but some of the drug is still physically lodged in the receptors it was built to block.
This finding has practical implications for how we think about ketamine’s duration of action. For anesthesia and analgesia, the plasma half-life is the most relevant number: once blood levels drop, sedation and pain relief fade in a reasonably predictable way. For depression treatment, the relevant “half-life” might be better described in terms of receptor occupancy rather than plasma concentration, and that timeline is far less well characterized. It also means that giving repeated doses at short intervals could lead to cumulative receptor trapping even if plasma levels have returned to baseline between doses.
S-Ketamine Versus R-Ketamine Clearance
Ketamine exists as two mirror-image molecules, S-ketamine (esketamine) and R-ketamine (arketamine), and they are not metabolized at exactly the same rate. In a study of healthy volunteers receiving the individual forms intravenously, R-ketamine had a slightly but significantly lower clearance rate than S-ketamine.21Springer Link. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity Standard racemic ketamine, which is a 50/50 mix of both forms, produces a blended pharmacokinetic profile. The prescription nasal spray Spravato uses only esketamine, and at-home oral or sublingual formulations typically use racemic ketamine, so the specific form you receive affects not only the potency and side-effect profile but also how quickly your body clears it.
The difference between the two enantiomers is modest in absolute terms, not large enough to dramatically change clinical decision-making on its own. But it adds another variable to the already wide range of reported half-lives and helps explain why two patients receiving the same nominal dose can have noticeably different experiences with how quickly the effects come on and fade.
Ketamine in Obese Patients
Body composition is another factor that can shift ketamine’s kinetics. Ketamine is highly lipophilic, meaning it readily dissolves into fat tissue. In someone with a higher proportion of body fat, more of the drug distributes into those fatty compartments during administration. This increases the drug’s apparent volume of distribution, which can extend the time it takes for blood levels to decline fully. The drug essentially has a larger reservoir to seep out of. Clinicians managing ketamine in obese patients often need to consider whether to dose based on actual body weight, lean body weight, or ideal body weight, since using actual weight in a very obese patient could lead to higher peak levels and a more prolonged tail of drug effect. There is no universally agreed-upon dosing strategy for this, which speaks to the broader reality that ketamine pharmacokinetics are more variable across individuals than many other commonly used drugs.